Achieve Life Sciences Inc (ACHV) Stock Price, Quote & News

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washing...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 210 2217

Website: www.achievelifesciences.com

Address:

22722 29th Dr. SE, Suite 100, Bothell, United States

Parnell8 Jan. 27 at 11:34 PM

$ACHV this S-3 is probably to register shares for the warrant exercise which gives them ample cash. We may not see an offering esp if they didn’t do one already when stock was over $5

1 · Reply

leshgo Jan. 27 at 10:28 PM

$ACHV If the stock dropped nearly 20% over two days just on an S-3 filing, imagine the crash if they actually announce a dilutive offering. Honestly, wouldn't it have been better to just execute the offering in the $6 range? It seems incredibly stupid to let the stock tank 20% on baseless fear alone. At least if they had raised the funds then, the disappointment would have been justified by the cash secured. I sold half my position before going to bed last night, and I’m very happy with that decision. I had a feeling management wouldn't respond to the panic. Sometimes it's wise to step aside and wait out the storm. I plan to increase my share count in the low $4 range.

0 · Reply

V106GuY Jan. 27 at 9:11 PM

$ACHV weeeeeeeeeeeee! Getting buy feelings

0 · Reply

Ralphbeach Jan. 27 at 8:13 PM

$ACHV Public Health Impact of FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation | Health Policy | JAMA Health Forum | JAMA Network https://share.google/BknvBYwZOntJOfzjU

1 · Reply

b3akohe Jan. 27 at 6:15 PM

$ACHV honestly not sure where the panic is . They are totally on track for their approval. They are doing their DD and still looking for partnership to market the approved meds . In case they don’t find perfect partner, they opened up a line that they can potentially tap into but don’t have to if not needed. So, to me this is very much anticipation technique and shows that they are planning and executing their plans . They won’t dilute if not necessary. I’m not understanding all the panic . I think it’s a perfect pre approval buying opportunity that everyone who doesn’t take advantage of it will greatly regret and soon

0 · Reply

leshgo Jan. 27 at 6:06 PM

$ACHV I was under the impression that for small-to-mid cap biotech companies like this, it typically takes a few days to get approval after filing an S-3, but I could be mistaken. For now, the large-scale outflow visible on the Webull app appears quite significant. From a bearish perspective, the fact that the price is dropping on higher-than-average volume suggests that further downside could be implied. Seeing such a sharp decline just on the news of potential capital raising makes me think that, as mentioned below, we might actually see the low $4 range.

2 · Reply

b3akohe Jan. 27 at 5:50 PM

$ACHV

1 · Reply

RaphaelRapoport Jan. 27 at 5:21 PM

$ACHV If they raise $100 million at $5.20 $100 million ÷ ~$5.50 ≈ 18.2 million new shares issued 53.2 million (existing) + 18.2 million (new) ≈ 71.4 million total shares after the raise. New implied per-share value ≈ $290 M ÷ 71.4 M ≈ $4.06/share So whoever called $4.10 isnt so off if they raised $100M -- I am going to wait to $4.30

1 · Reply

Jbg123 Jan. 27 at 5:08 PM

$ACHV need more information on whether Theres gonna be another dilution before I add more here. Still bullish

1 · Reply

CooperHandy Jan. 27 at 5:04 PM

$ACHV FWIW, I've not seen an ATM registered with the updated shelf (S-3). Feel free to share that filing(s) if I missed it 😉🤝

1 · Reply

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

Dec 17, 2025, 4:11 PM EST - 5 weeks ago

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Dec 8, 2025, 4:10 PM EST - 7 weeks ago

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

Nov 6, 2025, 3:26 PM EST - 2 months ago

Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 2 months ago

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Nov 3, 2025, 8:30 AM EST - 3 months ago

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

Oct 29, 2025, 8:30 AM EDT - 3 months ago

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

Oct 20, 2025, 8:30 AM EDT - 3 months ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

Oct 20, 2025, 7:15 AM EDT - 3 months ago

Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion

Oct 17, 2025, 7:30 AM EDT - 3 months ago

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Oct 2, 2025, 4:01 PM EDT - 4 months ago

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Sep 22, 2025, 8:30 AM EDT - 4 months ago

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Sep 18, 2025, 8:30 AM EDT - 4 months ago

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Sep 11, 2025, 5:01 PM EDT - 4 months ago

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

Sep 3, 2025, 8:30 AM EDT - 5 months ago

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Sep 2, 2025, 8:30 AM EDT - 5 months ago

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Aug 21, 2025, 2:11 PM EDT - 5 months ago

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Aug 8, 2025, 10:12 AM EDT - 6 months ago

Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:30 AM EDT - 6 months ago

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Jul 29, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 6 months ago

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

Jul 7, 2025, 1:55 PM EDT - 7 months ago

Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation

Jun 30, 2025, 7:52 PM EDT - 7 months ago

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

Jun 26, 2025, 11:43 PM EDT - 7 months ago

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

Jun 26, 2025, 4:03 PM EDT - 7 months ago

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Jun 26, 2025, 4:02 PM EDT - 7 months ago

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

OMC

Jun 3, 2025, 6:28 PM EDT - 8 months ago

Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk

May 28, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

May 13, 2025, 12:16 PM EDT - 9 months ago

Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 9 months ago

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

May 6, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Apr 21, 2025, 11:19 AM EDT - 10 months ago

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 11, 2025, 2:52 PM EDT - 11 months ago

Achieve Life Sciences, Inc. (ACHV) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 11 months ago

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Mar 7, 2025, 8:30 AM EST - 11 months ago

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

Mar 6, 2025, 8:30 AM EST - 11 months ago

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

Feb 11, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Jan 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Jan 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Dec 9, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

Dec 3, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Nov 25, 2024, 7:54 AM EST - 1 year ago

Smoking Cessation Pipeline Insight 2024, with Focus on Emerging Drugs Cytisinicline (Achieve Life Sciences), EMB-001(Embera Pharmaceuticals) and SBP-9330 (Camino Pharma)

Nov 9, 2024, 7:32 AM EST - 1 year ago

Achieve Life Sciences, Inc. (ACHV) Q3 2024 Earnings Call Transcript

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

Oct 1, 2024, 8:45 AM EDT - 1 year ago

Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

Aug 26, 2024, 4:30 PM EDT - 1 year ago

Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors

Aug 14, 2024, 4:58 AM EDT - 1 year ago

Achieve Life Sciences, Inc. (ACHV) Q2 2024 Earnings Call Transcript

Parnell8 Jan. 27 at 11:34 PM

$ACHV this S-3 is probably to register shares for the warrant exercise which gives them ample cash. We may not see an offering esp if they didn’t do one already when stock was over $5

1 · Reply

leshgo Jan. 27 at 10:28 PM

0 · Reply

V106GuY Jan. 27 at 9:11 PM

$ACHV weeeeeeeeeeeee! Getting buy feelings

0 · Reply

Ralphbeach Jan. 27 at 8:13 PM

$ACHV Public Health Impact of FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation | Health Policy | JAMA Health Forum | JAMA Network https://share.google/BknvBYwZOntJOfzjU

1 · Reply

b3akohe Jan. 27 at 6:15 PM

0 · Reply

leshgo Jan. 27 at 6:06 PM

2 · Reply

b3akohe Jan. 27 at 5:50 PM

$ACHV

1 · Reply

RaphaelRapoport Jan. 27 at 5:21 PM

1 · Reply

Jbg123 Jan. 27 at 5:08 PM

$ACHV need more information on whether Theres gonna be another dilution before I add more here. Still bullish

1 · Reply

CooperHandy Jan. 27 at 5:04 PM

$ACHV FWIW, I've not seen an ATM registered with the updated shelf (S-3). Feel free to share that filing(s) if I missed it 😉🤝

1 · Reply

Sieppo Jan. 27 at 4:25 PM

$ACHV there was a 844k share volume spike earlier on the 1min chart, more than the avg daily volume. Like Greyhound said, they might already be tapping the atm. Probably going to add some share more at some point.

0 · Reply

jeni1988 Jan. 27 at 4:14 PM

$ACHV Timi to load or wait???

1 · Reply

Ehri Jan. 27 at 4:12 PM

$ACHV Right. Management that leaves its investors so in the dark is bad management.

0 · Reply

MagnumPi1977 Jan. 27 at 4:01 PM

$ACHV Headlines spook people, but nothing changed today. PDUFA is still the story for $ACHV. Shelf just keeps options open after the decision.

1 · Reply

ItalianGreyhound Jan. 27 at 3:56 PM

For what it is worth I have not yet read the S3 filing, but I suspect it says that shares are effective as of its publication. I also would not be surprised if a first tranche of funds were being sold now to fund the vaping trial, and any negotiations are pending those results. Achieve is a much more valuable package with smoking + vaping and it also helps the buyer de-risk with more data. Clearly no offer was so outlandishly good it had to be accepted in San Francisco, and I believe Mr. Stewart is emboldened to go the Omnicom+cash route now that he knows the FDA is hopeful for cytisinicline to work. $ACHV

0 · Reply

PatienceisGrace Jan. 27 at 3:48 PM

$ACHV Saw a lot of ppl laughing at this guy. Maybe not so much now? May not hit $4.1 but already a significant drop from recent highs. Always take profit to some degree.

1 · Reply

Gdellinger Jan. 27 at 3:39 PM

$ACHV company has a great product but obviously ran by 🤡

0 · Reply

ItalianGreyhound Jan. 27 at 3:35 PM

$ACHV Shelf offering for $300MM and the possibility that the company may be tapping into it effective immediately -- it's a signal that discussions are still ongoing and more likely JP Morgan's presence in SF didn't do much to move the needle. All sides are very likely far apart for the valuation because of how depressed the current share price is relative to future potential value.

1 · Reply

MakeM0ney_444 Jan. 27 at 3:31 PM

$ACHV can someone please give cuffs as to why this is tanking the last few sessions

0 · Reply

markwall Jan. 27 at 8:58 AM

$ACHV Next quarterly report/conference call won't be till early March(6 weeks from now) for Q4 2025, based on past filings. Will the company stay silent till then?

1 · Reply

jkluv Jan. 27 at 8:07 AM

$ACHV 143 days until the target action date. I have a $3.34 average, and not going anywhere. Very Bullish.

1 · Reply

DistributionEquity Jan. 27 at 1:06 AM

$ACHV market doesn't like the S-3 but it makes total sense to put it in place. Creates the maximum flexibility / optionality, especially if / when approval comes in. Should the SP run, it only makes sense to take advantage of it.

1 · Reply

Market Cap	298.11M
Revenue (ttm)	0.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.04

Volume	2,586,000
Avg Vol	639,796
Day's Range	N/A - N/A
Shares Out	53.23M
Stochastic %K	8%
Beta	1.71
Analysts	Strong Sell
Price Target	$15.57